Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Other Non-Current Assets: 2012-2025

Historic Other Non-Current Assets for Veracyte (VCYT) over the last 13 years, with Sep 2025 value amounting to $1.6 million.

  • Veracyte's Other Non-Current Assets fell 79.20% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 79.20%. This contributed to the annual value of $7.0 million for FY2024, which is 16.92% up from last year.
  • Veracyte's Other Non-Current Assets amounted to $1.6 million in Q3 2025, which was down 1.03% from $1.7 million recorded in Q2 2025.
  • Veracyte's Other Non-Current Assets' 5-year high stood at $7.9 million during Q3 2024, with a 5-year trough of $749,000 in Q4 2021.
  • In the last 3 years, Veracyte's Other Non-Current Assets had a median value of $6.0 million in 2023 and averaged $5.6 million.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 697.20% in 2023, then slumped by 79.20% in 2025.
  • Veracyte's Other Non-Current Assets (Quarterly) stood at $749,000 in 2021, then remained steady at $749,000 in 2022, then soared by 697.20% to $6.0 million in 2023, then rose by 16.92% to $7.0 million in 2024, then tumbled by 79.20% to $1.6 million in 2025.
  • Its Other Non-Current Assets stands at $1.6 million for Q3 2025, versus $1.7 million for Q2 2025 and $7.1 million for Q1 2025.